Drug Type Synthetic peptide |
Synonyms Tirzepatide (USAN), TZP, ZEHP-bownd + [12] |
Target |
Action agonists |
Mechanism GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (13 May 2022), |
RegulationPriority Review (United States), Fast Track (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11360 | Tirzepatide | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Obesity Hypoventilation Syndrome | China | 30 Jun 2025 | |
Sleep Apnea, Obstructive | United States | 20 Dec 2024 | |
Obesity | United States | 08 Nov 2023 | |
Overweight | United States | 08 Nov 2023 | |
Weight Gain | Australia | 23 Dec 2022 | |
Diabetes Mellitus, Type 2 | United States | 13 May 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Heart failure with normal ejection fraction | NDA/BLA | China | 22 Nov 2024 | |
Colitis, Ulcerative | Phase 3 | United States | 26 Jun 2025 | |
Colitis, Ulcerative | Phase 3 | Austria | 26 Jun 2025 | |
Colitis, Ulcerative | Phase 3 | Belgium | 26 Jun 2025 | |
Colitis, Ulcerative | Phase 3 | Brazil | 26 Jun 2025 | |
Colitis, Ulcerative | Phase 3 | Bulgaria | 26 Jun 2025 | |
Colitis, Ulcerative | Phase 3 | Canada | 26 Jun 2025 | |
Colitis, Ulcerative | Phase 3 | Croatia | 26 Jun 2025 | |
Colitis, Ulcerative | Phase 3 | Czechia | 26 Jun 2025 | |
Colitis, Ulcerative | Phase 3 | Denmark | 26 Jun 2025 |
Phase 3 | 1,605 | gukrmcpvzf(pyurfyvkoe) = nummjiwxgm povndqfaxc (sebzlqezdu, -63.6% - -55.3%) View more | Positive | 24 Jun 2025 | |||
Phase 1 | 114 | nbkqgluwip(rgphkpvaiy) = hkptgdmynd toxuaooiqk (uqvgbfwfer, -648.1 to -401.0) | Positive | 24 Jun 2025 | |||
Placebo | - | ||||||
NEWS Manual | Not Applicable | - | aisuehsmeg(wyfdukzzqk) = ksudgzciut ccazdmpbqn (fhvrtmgflm ) View more | - | 10 Jun 2025 | ||
Not Applicable | - | kkbzfrfeqg(ewqxoanlim) = rfhezekdqe jkphwyyqmr (zfxgzhtuvp ) | Positive | 30 May 2025 | |||
GLP-1 receptor agonists | kkbzfrfeqg(ewqxoanlim) = gwxwvalfuh jkphwyyqmr (zfxgzhtuvp ) | ||||||
Not Applicable | - | GIP/GLP-1 co-agonist | tshwobzali(skgoqszhif): HR = 1.03 (95% CI, 0.88 - 1.21) View more | Positive | 16 May 2025 | ||
GLP-1 agonist | |||||||
Not Applicable | - | tprwbifqtb(ghucauxrfn) = AKI (creatinine 2.38) mtphjxpxtt (kduwmzsolo ) View more | Negative | 16 May 2025 | |||
Phase 3 | - | mxphuelehy(ommzclyjge) = eydvzxtgnc rjyeozulvl (zmmrminwgo ) View more | Positive | 16 May 2025 | |||
mxphuelehy(ommzclyjge) = uofomlksxx rjyeozulvl (zmmrminwgo ) View more | |||||||
Not Applicable | - | GLP-1 agonists | wxhqvmmwry(ktwouteffc): HR = 0.62 (95% CI, 0.53 - 0.74), P-Value = <0.01 | Positive | 16 May 2025 | ||
Glucagon-Like Peptide-1 Agonists (No GLP-1 agonists) | |||||||
Phase 4 | 282 | hynlxfslee(xkeioobbpg) = ucxuhnpujf fnwhnwyetg (guodomylsf, 0.07) View more | Positive | 01 May 2025 | |||
hynlxfslee(xkeioobbpg) = jcjwohuyil fnwhnwyetg (guodomylsf, 0.08) View more | |||||||
Phase 3 | 469 | (Tirzepatide MTD_GPI1) | yyisvwrcqm(grjourrxei) = psogzcbrin yvureeunnn (codqaffyiq, 2.06) View more | - | 30 Apr 2025 | ||
Placebo (Placebo_GPI1) | yyisvwrcqm(grjourrxei) = yyogytrvzs yvureeunnn (codqaffyiq, 2.11) View more |